ACRS
Aclaris Therapeutics Inc

4,940
Mkt Cap
$283.86M
Volume
765,910.00
52W High
$3.48
52W Low
$1.05
PE Ratio
-1.90
ACRS Fundamentals
Price
$2.62
Prev Close
$2.67
Open
$2.69
50D MA
$2.77
Beta
1.18
Avg. Volume
1.19M
EPS (Annual)
-$1.71
P/B
2.36
Rev/Employee
$292,500.00
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans
Aclaris Therapeutics (NASDAQ:ACRS) hosted an investor conference call on January 6, 2026 to discuss positive interim results from its ongoing first-in-human Phase 1a single ascending dose (SAD) and...
MarketBeat·14d ago
News Placeholder
More News
News Placeholder
Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS
Three Bridge Wealth Advisors LLC purchased a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 3rd quarter, according to the company in its most recent Form...
MarketBeat·17d ago
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat reports...
MarketBeat·22d ago
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Has Strong Outlook for ACRS FY2025 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Sunday...
MarketBeat·2mo ago
News Placeholder
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten analysts that are currently covering the company...
MarketBeat·2mo ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of...
MarketBeat·2mo ago
News Placeholder
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.69% and +107.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
Corcept (CORT) delivered earnings and revenue surprises of -11.11% and -5.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·3mo ago
<
1
2
...
>

Latest ACRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.